These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38674298)

  • 1. Effects of the Neuropeptides Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Peptide in Male Fertility.
    Bdeir R; Al-Keilani MS; Khamaiseh K
    Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674298
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
    Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
    Drahushuk K; Connell TD; Higgins D
    J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
    Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
    Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs.
    Dickinson T; Fleetwood-Walker SM; Mitchell R; Lutz EM
    Neuropeptides; 1997 Apr; 31(2):175-85. PubMed ID: 9179871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive intestinal polypeptide- and pituitary adenylate cyclase activating polypeptide-mediated control of catecholamine release from chromaffin tissue in the rainbow trout, Oncorhynchus mykiss.
    Montpetit CJ; Perry SF
    J Endocrinol; 2000 Sep; 166(3):705-14. PubMed ID: 10974664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis.
    Baranowska-Bik A; Kochanowski J; Uchman D; Wolinska-Witort E; Kalisz M; Martynska L; Baranowska B; Bik W
    J Neuroimmunol; 2013 Oct; 263(1-2):159-61. PubMed ID: 24041830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
    Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
    Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary adenylate cyclase-activating polypeptide regulates rat Leydig cell function in vitro.
    Romanelli F; Fillo S; Isidori A; Conte D
    Neuropeptides; 1997 Aug; 31(4):311-7. PubMed ID: 9308016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anorexigenic effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide in the chick brain are mediated by corticotrophin-releasing factor.
    Tachibana T; Saito ES; Takahashi H; Saito S; Tomonaga S; Boswell T; Furuse M
    Regul Pept; 2004 Aug; 120(1-3):99-105. PubMed ID: 15177926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
    Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
    Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of mRNAs for pituitary adenylate cyclase-activating polypeptide (PACAP), PACAP receptor, vasoactive intestinal polypeptide (VIP), and VIP receptors in the rat superior cervical ganglion.
    Nogi H; Hashimoto H; Hagihara N; Shimada S; Yamamoto K; Matsuda T; Tohyama M; Baba A
    Neurosci Lett; 1997 May; 227(1):37-40. PubMed ID: 9178853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum.
    Hedlund P; Alm P; Ekström P; Fahrenkrug J; Hannibal J; Hedlund H; Larsson B; Andersson KE
    Br J Pharmacol; 1995 Oct; 116(4):2258-66. PubMed ID: 8564257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between vasoactive intestinal polypeptide and pituitary adenylate cyclase activating polypeptide levels in neuroblastoma tumour tissues.
    Vertongen P; De Clerck P; Fournet JC; Martelli H; Hélardot P; Devalck C; Peeters T; Sariban E; Robberecht P
    Neuropeptides; 1997 Oct; 31(5):409-13. PubMed ID: 9413016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on hormone secretion from sheep pituitary cells in vitro.
    Sawangjaroen K; Anderson ST; Curlewis JD
    J Neuroendocrinol; 1997 Apr; 9(4):279-86. PubMed ID: 9147291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
    Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
    Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.